Please assess the completion status of the following clinical trial:

Trial Title: A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged ≥18 and ≤75 years who have signed an Informed Consent Form prior to initiation of any study-related procedure.~* A diagnosis of asthma as defined in the Global Initiative for Asthma (GINA) Report, 2016, documented for at least 1 year prior to screening.~* Poorly controlled or uncontrolled asthma evidenced by a score ≥1.5 on the Asthma Control Questionnaire 7 © (ACQ-7)~* A pre-bronchodilator Forced Expiratory Volume in the 1st Second ( FEV1) ≥60% and \<85% of their predicted normal value, after appropriate washout from bronchodilators, at the screening and randomization visits~* Subjects with a positive response to a reversibility test at screening, defined as change in FEV1 (ΔFEV1) ≥12% and ≥200 mL over baseline within 30 minutes after inhaling 4 puffs of albuterol hydrofluoroalkane(HFA) 90 µg/actuation.~* Use of ICS (low/medium dose according to GINA Report, 2016) with or without a long-acting bronchodilator for 3 months (at a stable dose in the last 4 weeks) before screening visit.~* A cooperative attitude and ability to demonstrate correct use of the diary, peak flow meter, and pMDI inhaler.~Exclusion Criteria:~* Pregnant or lactating women and all women physiologically capable of becoming pregnant UNLESS they are willing to use a highly effective birth control methods~* Subjects who suffer from Chronic Obstructive Pulmonary Disease (COPD) as defined by the Global Strategy for Prevention, Diagnosis and Management of COPD (GOLD) Report, 2017, or are suspected of having Asthma COPD Overlap Syndrome (ACOS) as described in the GINA Report, 2016.~* Inability to carry out pulmonary function testing, to comply with study procedures or with study drug intake.~* Current smokers or ex-smokers (tobacco, vapor cigarettes, marijuana) with a smoking history of \>10 pack-years or having stopped smoking one year or less prior to screening visit.~* History of life-threatening asthma, clinically significant uncontrolled disease or respiratory infection.~* An asthma exacerbation requiring oral/intravenous corticosteroids ≤ 30 days, intramuscular depot corticosteroid ≤3 months or hospitalization within 6 months prior to screening.~* Subjects with unresolved bacterial or viral respiratory tract, sinus, or middle ear infection affecting asthma status within 2 weeks prior to screening.~* Subjects who received a vaccination within 2 weeks prior to screening or during the run-in.~* Subjects with oral candidiasis at screening and at randomization.~* Subjects with any clinically significant, uncontrolled condition.~* Subjects with serum potassium levels \<3.5 milliequivalents per litre (mEq/L) or (3.5 mmol/L) at screening.~* Subjects who have clinically significant cardiovascular condition.~* Subjects who have a clinically significant abnormal 12-lead ECG that results in active medical problem which may impact the safety of the patient according to Investigator's judgment.~* Subjects whose 12-lead ECG shows Fridericia's corrected QT interval (QTcF) \>450 ms for males or QTcF \>470 ms for females at screening or randomization visits.~* Subjects with known intolerance/hypersensitivity or contra-indication to treatment with inhaled β2-adrenergic receptor agonists, corticosteroids or propellant gases/excipients.~* Subjects with concomitant immunosuppressive therapy, use of oral or injected corticosteroids, anti- Immunoglobulin E (IgE), anti-Interleukin 5 (IL5) or other monoclonal or polyclonal antibodies within 12 weeks prior to screening.~* Use of potent cytochrome P450 3A4 inhibitors and inducers within 4 weeks prior to screening.~* History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening.~* Subjects who have received an investigational drug within 1 month or 5 half-lives (whichever is greater) prior to screening visit, or have been previously randomized in this trial, or are currently participating in another clinical trial.~* Subjects who are mentally or legally incapacitated or subjects accommodated in an establishment as a result of an official or judicial order.~* Subjects who have undergone major surgery in the 3 months prior to screening visit or have a planned surgery during the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): Treatment A, CHF 1531 pMDI:~CHF 1531 pMDI 6 μg total daily dose (TDD):~1 inhalation of CHF 1531 pMDI 3 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID.
- Treatment B (Type: EXPERIMENTAL): Treatment B, CHF 1531 pMDI:~CHF 1531 pMDI 12 μg TDD:~1 inhalation of CHF 1531 pMDI 6 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID.
- Treatment C (Type: EXPERIMENTAL): Treatment C, CHF 1531 pMDI:~CHF 1531 pMDI 24 μg TDD: 2 inhalations of CHF 1531 pMDI 6 μg/actuation BID.
- Treatment D (Type: EXPERIMENTAL): Treatment D, CHF 1531 pMDI~CHF 1531 pMDI 48 μg TDD: 2 inhalations of CHF 1531 pMDI 12 μg/actuation BID.
- Treatment E (Type: EXPERIMENTAL): Treatment E, Matched placebo~Placebo: 2 inhalations of CHF 1531 pMDI matched Placebo BID.
- Treatment F (Type: ACTIVE_COMPARATOR): Treatment F, Formoterol fumarate inhalation solution (IS)~Perforomist® IS (active comparator, open-label) 40 μg TDD: 1 inhalation, 20 μg/ 2 mL vial, 1 vial BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).